Phase I Rux+Fosta for Steroid Refractory cGvHD (Graft versus Host Disease) - Clinical Trial

¿Cuál es el Propósito de este estudio?

We are doing this study to find out if an investigational drug called fostamatinib (the study drug) is beneficial for cGvHD when it is used in combination with a standard of care drug, ruxolitinib. We want to know if the study drug can improve relief from cGvHD symptoms.

¿Cuál es la Condición que se está estudiando?

Chronic Graft Versus Host Disease (cGvHD)

¿Quién puede participar en el Estudio?

Adultos de 18 a 80 años que:

Are diagnosed with cGvHD
Are either dependent on steroids or non-responsive to steroids
Have received an allogeneic hematopoietic cell transplant (HCT)

For more information about who can join this study, please contact one of the study team members below:

Chenyu Lin: chenyu.lin@duke.edu or 919-684-8964

Michelle Araque: michelle.araque@duke.edu or 919-660-0982

Grupo etario

Adultos

¿Qué Implica?

Si decide participar en el estudio, podrá:

Have a physical exam done and medical history taken
Have vital signs taken
Realizar extracciones de sangre
Have a pulmonary function (breathing) test
Fill out questionnaires
Take a combination of the study drug and ruxolitinib (pills that you take by mouth)